Itaconate-based metabolic therapy for neurological disorders

Overview

This research program advances a novel therapeutic approach that uses itaconate, an endogenous anti-inflammatory metabolite, to restore metabolic balance and protect neurons in neurological disorders. By transiently modulating mitochondrial enzyme activity, itaconate reduces oxidative stress, dampens neuroinflammation, and preserves neuronal viability. The work focuses on understanding how this metabolite reprograms brain cell metabolism to slow disease progression, offering a new angle on treating conditions driven by neuroinflammation and metabolic dysfunction.

Technical specifications

• Mechanism of action: Itaconate transiently inhibits succinate dehydrogenase (SDH) activity, elevating succinate levels and shifting cellular metabolism toward protective pathways.
• Antioxidant activation: Itaconate activates Nrf2-regulated antioxidant pathways in primary brain cells, reducing reactive oxygen species and oxidative injury.
• Hemodynamic benefits: In vivo studies show that itaconate preserves blood flow in multiple brain regions, improving oxygen delivery and tissue oxygenation.
• Anti-inflammatory effects: Itaconate reprograms intermediary metabolism and inflammatory signaling in cortical neurons, astrocytes, and microglia.
• Rapid clearance: Itaconate is rapidly cleared in vivo, supporting a controlled, transient therapeutic effect without prolonged metabolic disruption.
• Validation tools: Metabolic flux analysis, primary cell culture models, and animal models of neurological disorders are used to assess metabolic, redox, and inflammatory outcomes.

Technology readiness level

Preliminary data demonstrate that itaconate preserves brain function, reduces inflammation, and improves hemodynamics in established disease models. Cultured cortical neuron and astrocyte studies confirm metabolic reprogramming and Nrf2 activation. Future validation will expand these findings through detailed metabolic flux studies in cultured neurons and glial cells and through administration studies in mouse models of neurological disorders to assess physiological, metabolic, and functional outcomes. The approach is currently at the preclinical research stage.